Literature DB >> 34474962

Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry.

Justin Mak1, Tina M Cowan2.   

Abstract

BACKGROUND: Urine and plasma biomarker testing for lysosomal storage disorders by liquid chromatography mass spectrometry (LC-MS) currently requires multiple analytical methods to detect the abnormal accumulation of oligosaccharides, mucopolysaccharides, and glycolipids. To improve clinical testing efficiency, we developed a single LC-MS method to simultaneously identify disorders of oligosaccharide, mucopolysaccharide, and glycolipid metabolism with minimal sample preparation.
METHODS: We created a single chromatographic method for separating free glycans and glycolipids in their native form, using an amide column and high pH conditions. We used this glycomic profiling method both in untargeted analyses of patient and control urines using LC ion-mobility high-resolution MS (biomarker discovery), and targeted analyses of urine, serum, and dried blood spot samples by LC-MS/MS (clinical validation).
RESULTS: Untargeted glycomic profiling revealed twenty biomarkers that could identify and subtype mucopolysaccharidoses. We incorporated these with known oligosaccharide and glycolipid biomarkers into a rapid test that identifies at least 27 lysosomal storage disorders, including oligosaccharidoses, mucopolysaccharidoses, sphingolipidoses, glycogen storage disorders, and congenital disorders of glycosylation and de-glycosylation. In a validation set containing 115 urine samples from patients with lysosomal storage disorders, all were unambiguously distinguished from normal controls, with correct disease subtyping for 88% (101/115) of cases. Glucosylsphingosine was reliably elevated in dried blood spots from Gaucher disease patients with baseline resolution from galactosylsphingosine.
CONCLUSION: Glycomic profiling by liquid chromatography mass spectrometry identifies a range of lysosomal storage disorders. This test can be used in clinical evaluations to rapidly focus a diagnosis, as well as to clarify or support additional gene sequencing and enzyme studies.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker discovery; Glycomics; Inborn errors of metabolism; Liquid chromatography mass spectrometry; Lysosomal storage disorders; Metabolomics

Mesh:

Substances:

Year:  2021        PMID: 34474962      PMCID: PMC9069563          DOI: 10.1016/j.ymgme.2021.08.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.204


  43 in total

1.  Profiling oligosaccharidurias by electrospray tandem mass spectrometry: quantifying reducing oligosaccharides.

Authors:  Steven L Ramsay; Peter J Meikle; John J Hopwood; Peter R Clements
Journal:  Anal Biochem       Date:  2005-10-01       Impact factor: 3.365

2.  Setup and Validation of a Targeted Next-Generation Sequencing Approach for the Diagnosis of Lysosomal Storage Disorders.

Authors:  Alessandra Zanetti; Francesca D'Avanzo; Loris Bertoldi; Guido Zampieri; Erika Feltrin; Fabio De Pascale; Angelica Rampazzo; Monica Forzan; Giorgio Valle; Rosella Tomanin
Journal:  J Mol Diagn       Date:  2020-02-07       Impact factor: 5.568

3.  Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience.

Authors:  Barbara K Burton; Joel Charrow; George E Hoganson; Darrell Waggoner; Brad Tinkle; Stephen R Braddock; Michael Schneider; Dorothy K Grange; Claudia Nash; Heather Shryock; Rebecca Barnett; Rong Shao; Khaja Basheeruddin; George Dizikes
Journal:  J Pediatr       Date:  2017-07-17       Impact factor: 4.406

4.  Urine oligosaccharide screening by MALDI-TOF for the identification of NGLY1 deficiency.

Authors:  Patricia L Hall; Christina Lam; John J Alexander; Ghazia Asif; Gerard T Berry; Carlos Ferreira; Hudson H Freeze; William A Gahl; Kim K Nickander; Jon D Sharer; Caroline M Watson; Lynne Wolfe; Kimiyo M Raymond
Journal:  Mol Genet Metab       Date:  2018-03-10       Impact factor: 4.797

5.  A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.

Authors:  Ashlee R Stiles; Haoyue Zhang; Jian Dai; Patricia McCaw; James Beasley; Catherine Rehder; Dwight D Koeberl; Marie McDonald; Deeksha S Bali; Sarah P Young
Journal:  Mol Genet Metab       Date:  2020-05-03       Impact factor: 4.797

6.  UPLC-MS/MS Analysis of Urinary Free Oligosaccharides for Lysosomal Storage Diseases: Diagnosis and Potential Treatment Monitoring.

Authors:  Rongrong Huang; Sara Cathey; Laura Pollard; Tim Wood
Journal:  Clin Chem       Date:  2018-09-10       Impact factor: 8.327

7.  Variability of Two Metabolomic Platforms in CKD.

Authors:  Eugene P Rhee; Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Regis Perichon; Clary B Clish; Anne M Evans; Julian Avila; Michelle R Denburg; Amanda Hyre Anderson; Ramachandran S Vasan; Harold I Feldman; Paul L Kimmel; Josef Coresh
Journal:  Clin J Am Soc Nephrol       Date:  2018-12-20       Impact factor: 10.614

8.  Assessment of a targeted resequencing assay as a support tool in the diagnosis of lysosomal storage disorders.

Authors:  Ana Fernández-Marmiesse; Marcos Morey; Merce Pineda; Jesús Eiris; Maria Luz Couce; Manuel Castro-Gago; Jose Maria Fraga; Lucia Lacerda; Sofia Gouveia; Maria Socorro Pérez-Poyato; Judith Armstrong; Daisy Castiñeiras; Jose A Cocho
Journal:  Orphanet J Rare Dis       Date:  2014-04-25       Impact factor: 4.123

9.  Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry.

Authors:  Susan Elliott; Norman Buroker; Jason J Cournoyer; Anna M Potier; Joseph D Trometer; Carole Elbin; Mack J Schermer; Jaana Kantola; Aaron Boyce; Frantisek Turecek; Michael H Gelb; C Ronald Scott
Journal:  Mol Genet Metab       Date:  2016-05-20       Impact factor: 4.797

10.  Untargeted Metabolomics-Based Screening Method for Inborn Errors of Metabolism using Semi-Automatic Sample Preparation with an UHPLC- Orbitrap-MS Platform.

Authors:  Ramon Bonte; Michiel Bongaerts; Serwet Demirdas; Janneke G Langendonk; Hidde H Huidekoper; Monique Williams; Willem Onkenhout; Edwin H Jacobs; Henk J Blom; George J G Ruijter
Journal:  Metabolites       Date:  2019-11-26
View more
  1 in total

1.  GlcNAc-Asn is a biomarker for NGLY1 deficiency.

Authors:  William F Mueller; Lei Zhu; Brandon Tan; Selina Dwight; Brendan Beahm; Matt Wilsey; Thomas Wechsler; Justin Mak; Tina Cowan; Jake Pritchett; Eric Taylor; Brett E Crawford
Journal:  J Biochem       Date:  2022-02-21       Impact factor: 3.387

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.